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Abstract
Myxopapillary ependymoma (MEPN) generally can be cured by gross total surgical resec-
tion and usually manifest a favorable prognosis. However, surgery is less curative in tumors
that are large, multifocal or extend outside the thecal sac. Late recurrences may occur,
particularly in pediatric patients. The role of adjuvant therapy is unclear in the clinical
management of recurrent tumors. Clinical trial design requires a better understanding of
tumor biology. Unique molecular features of MEPN were investigated by using microarray
technology to compare the gene expression of ﬁve pediatric MEPN to 24 pediatric intracra-
nial ependymoma (EPN). The upregulation of three genes of interest, homeobox B13
(HOXB13), neuroﬁlament, light polypeptide (NEFL) and PDGFRa, was further studied by
immunohistochemistry in a larger cohort that included adult MEPN and EPN specimens.
Protein expression in MEPN was compared to subependymoma, spinal EPN, intracranial
EPN and normal fetal and adult ependyma. Immunoreactivity for HOXB13, NEFL and
PDGFRa was strongest in MEPN and virtually absent in subependymoma. Spinal and
intracranial EPN generally expressed weak or focal staining. MEPN manifests unique gene
and protein expression patterns compared to other EPNs.Aberrant expression of HOXB13
suggests possible recapitulation of developmental pathways in MEPN tumorigenesis.
PDGFRa may be a potential therapeutic target in recurrent MEPN.
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INTRODUCTION
Myxopapillary ependymoma (MEPN) is a slow-growing ependy-
moma type that is virtually conﬁned to the conus medullaris-cauda
equina-ﬁlumterminaleregionofthespinalcord(8).Histologically,
MEPN is characterized by a papillary arrangement of tumor cells
around vascularized myxoid stromal cores and corresponds to
World Health Organization (WHO) grade I. MEPN constitutes
approximately 13% of ependymoma (EPN) (32).Age of diagnosis
ranges from 6 to 82 years with an average age of 36.4 years (10).
Standard treatment of MEPN is aggressive surgery. However,
tumor recurrence can occur with incomplete resection and the role
of adjuvant chemotherapy (25, 36, 37) or radiotherapy (30, 33, 41)
is unresolved for the subset of patients with recurrence or in
patients in whom gross total resection cannot be achieved.
Pediatric patients are more likely to develop metastases and
display a more aggressive course of disease (11, 16, 17, 22). A
recent study by Bagley et al. examined the clinical course of 52
MEPN including 14 pediatric patients and 38 adult patients (5).
Pediatric patients had a higher rate of local recurrence and tumor
dissemination within the neural axis (64% compared to 32%).
Although these numbers are higher than previously reported in the
literature, they are likely to be more accurate due to the study’s
long-term follow-up (11.5 years). No beneﬁt for adjuvant chemo-
therapy or radiation therapy was demonstrated.
Clinical trial design for novel adjuvant therapies mandates
better knowledge of the biology of MEPN. Few studies have
examined the molecular biology of MEPN compared to intracra-
nial and spinal EPN tumors. In a study of 62 ependymal tumors
including six MEPN, Ebert et al found six NF2 mutations in
grade II spinal EPN but no mutations in MEPN (14). Santi et al
investigated chromosome 7 copy number in 27 adult EPN,
including 13 MEPN, by chromogenic in situ hybridization. All 13
of the MEPN tested displayed polysomy of chromosome 7 in
contrast to the other EPN, which were diploid (31). A study by
Lukashova-v Zangen et al compared the gene expression of eight
MEPN and six subependymomas (SEPN) by cDNA microarray
and real-time polymerase chain reaction (21). They reported 30
genes that were more highly expressed in SEPN than MEPN
including ETV6, YWHAE, TOP2A, TLR2, ADE2H1, IRAK1,
TIA1, TTL, UFD1L, TOMM70A and HSD3B1. Unique molecu-
lar characteristics of MEPN were not described. Finally, Kor-
shunov et al examined 39 ependymal neoplasms including four
MEPN by microarray (19). MEPN were found to be molecularly
distinct from intracranial EPN, with high expression of HOXB5,
PLA2G5 and ITIH2. However, the study reported only three
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protein expression data.
The aforementioned studies suggest that MEPN is molecularly
distinct from other types of EPN but provide few clues into the
biologyofthesetumors.Noveltherapiesmaybeespeciallypertinent
topediatricMEPN,whichhaveamoreaggressivecourseofdisease
thatisclinicallydifﬁculttocontroldespitethedeceptively“benign”
WHO grade I designation. The present study uses microarray and
immunohistochemistry (IHC) to compare the biology of pediatric
MEPNandintracranialEPNtoidentifyuniquemolecularcharacter-
isticsofMEPNandpotentialtherapeutictargets.
METHODS
Study cohort
A retrospective analysis was performed on tumor specimens
obtained from The Children’s Hospital, Denver or University of
Colorado Hospital.All studies were conducted in compliance with
local and federal human research protection guidelines and institu-
tionalreviewboardregulations(COMIRB#95-500and#08-0944).
Gene expression microarray analysis was conducted on ﬁve
pediatric MEPN and 23 pediatric intracranial EPN. In addition
to the ependymoma variants, 50 other pediatric central nervous
system (CNS) tumor specimens were analyzed by microarray
including 18 glioblastomas (GBM), 10 pilocytic astrocytomas
(PA),nineatypicalteratoid/rhabdoidtumors(ATRT),nineclassical
medulloblastomas (MED) and four large-cell medulloblastomas
(LCM).
IHC specimens included 13 MEPN (ﬁve pediatric, eight adult),
eight spinal EPN (one pediatric, seven adult), 12 intracranial EPN
(sevensupratentorial,ﬁveinfratentorial;sevenpediatric,ﬁveadult)
and ﬁve adult SEPN. The diagnosis, age, gender and grade of
tumors included in the IHC study are summarized in supporting
informationTable S1.Conus medullaris and ﬁlum terminale spinal
cord sections from ﬁve adult patients who did not suffer from
neurological disease were included in the analysis. Spinal cord
sections from three fetuses of 18, 23 and 35 weeks’ gestation were
also included in the analysis.
Gene expression microarray analysis
Patient tumor samples were evaluated for gene expression using
Affymetrix U133 Plus2 GeneChip microarrays (Santa Clara, CA,
USA). Samples were collected at the time of surgery and snap-
frozen in liquid nitrogen. RNA was extracted from each sample
using an RNeasy kit (Qiagen,Valencia, CA, USA) according to the
manufacturer’s instructions and RNA quality was measured using
a 2100 BioAnalyser (Agilent, Santa Clara, California USA). RNA
was processed as described previously (12) and hybridized to
HG-U133 Plus2 GeneChips (Affymetrix) according to the manu-
facturer’s instructions. Microarray data from the samples was
background-correctedandnormalizedusingthegcRMAalgorithm
(45). One probe set per gene, based on highest overall expression
level across samples, was selected for use in subsequent analyses.
Differential expression of genes was determined using a Student’s
t-test.The false discovery rate, as deﬁned by Benjamini et al., was
setat<0.05forallt-tests(7).
For clustering, data were ﬁltered to include only genes that
showed at least moderate expression (expression value greater than
5) and a range of expression values across all samples (only the top
one-thirdofgenesasrankedbytheexpressionrange)wereusedfor
the clustering analysis. These criteria resulted in the selection of
6414 genes. The hierarchical clustering used an agglomerative
algorithm with average linkage and Euclidean distances, as imple-
mented in the hclust package (35). Relative statistical strength of
the resulting dendrogram branches was estimated using multiscale
bootstrap resampling to estimate P values for each branch, based
on 1000 replications, as implemented in pvclust. All R pack-
ages used are available through Bioconductor (http://www.
bioconductor.org) or CRAN (http://cran.r-project.org).
Immunohistochemistry (IHC)
IHC was performed on parafﬁn-embedded tumor tissue sections.
All sections were immunostained in batch fashion. Slides were
deparafﬁnized and antigen retrieval was performed using LPH
Buffer (BioCare Medical, Concord, CA, USA) for 60 minutes
at 93°C followed by a 20-minute cool down. Subsequent steps
were performed using the EnVision-HRP kit (Dako, Glostrup,
Denmark) on a Dako autostainer according to the standard proto-
col. Incubation with primary antibody was performed for 2 h.
Antibodies for IHC included rabbit polyclonal anti-PDGFRa at a
1:200 dilution (sc-338; Santa Cruz Biotechnology, Santa Cruz,
CA, USA), rabbit monoclonal anti-neuroﬁlament, light polypep-
tide (NEFL) at a 1:100 dilution (2837S; Cell Signaling Technol-
ogy, Danvers, MA, USA), and mouse monoclonal anti-homeobox
B13 (HOXB13) at a 1:200 dilution (sc-28333; Santa Cruz
Biotechnology).
Immunostainingwasscoredbytheneuropathologist(BKD),who
wasblindedtothediagnosisorspeciﬁccasenumber.Allscoringwas
conducted twice over a several-day interval for concordance.After
reviewing the slides in blinded fashion, the code was broken and
slides were re-grouped according to histological diagnosis for the
ﬁnal review. The overall impression was the same as the original
review, but this allowed direct comparisons between cases with
similar diagnoses. Immunostaining was scored from - to ++ on a
subjective scale. Twenty-ﬁve percent to 100% of cells staining
yieldedascoreof++.Veryfocalstaininginindividualcellsyieldeda
scoreof+.Absenceofstainingwasgivena-designation.
Statistical analysis
Statistical calculations were analyzed with R (http://cran.r-
project.org/), Bioconductor (http://www.bioconductor.org) and
Prism statistical analysis program (GraphPad Software, Inc., San
Diego, CA). For all tests, a level of P < 0.05 was considered statis-
tically signiﬁcant.
RESULTS
Patient demographics
Patient details including diagnosis, age at diagnosis, gender and
tumor grade are summarized in supplemental information
Table S1. Brieﬂy, the median age of pediatric MEPN patient
diagnosis was 13 (ages ranged from 12 to 17 years). The male to
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sis was 3 years for pediatric intracranial EPN (age ranged from 0.5
to 18 years). Fifty-two percent of pediatric intracranial EPN corre-
sponded toWHO grade II and 48% were grade III. Seventy percent
of pediatric EPN were infratentorial and 30% were supratentorial.
The male to female ratio was 1.3:1.0.
Gene expression microarray in MEPN compared
to intracranial EPN
A clustering analysis of EPN gene expression proﬁles showed that
pediatric MEPN (n = 5) formed a distinct subgroup from pediatric
intracranial EPN (n = 24) (Figure 1). This analysis suggests that
gene expression of MEPN is distinct from other intracranial EPN.
Supratentorial and infratentorial EPN further divided into distinct
subgroups.Theassociationbetweenmolecularsignatureandtumor
location in intracranial EPN has previously been reported by
Modena et al (23).
Table 1 displays the top 15 over- and underexpressed genes in
MEPN compared to intracranial EPN. Genes are ranked accorded
Figure 1. Hierarchical clustering analysis of the myxopapillary subgroup
of ependymoma. Gene expression proﬁles of ﬁrst presentation surgical
samples of ﬁve pediatric MEPN and 24 pediatric intracranial EPN.
Numerical values represent approximately unbiased P values that were
computed by multiscale bootstrap resampling. Abbreviations: EPN =
ependymoma; MEPN = myxopapillary ependymoma; IF = infratentorial;
ST = supratentorial.
Table 1. Top 15 over- and underexpressed genes in pediatric myxopapillary versus pediatric intracranial ependymoma. Genes are ranked according to
greatest statistical signiﬁcance. In addition to the P values, q values are listed as a measure of the false discovery rate which estimates the probability
of a false positive ﬁnding. The probe ID identiﬁes the Affymetrix U133 Plus2 GeneChip probe set.
Gene symbol Gene name Probe ID P value q value
Genes overexpressed in myxopapillary ependymoma
PRAC Small nuclear protein 230784_at 1.00E-34 1.92E-30
HOXB13 Homeobox B13 209844_at 7.78E-33 7.49E-29
ARL15 Adp-ribsolyation factor-like 15 219842_at 1.47E-24 9.43E-21
HOXC10 Homeobox c10 218959_at 3.64E-24 1.40E-20
NEFL Neuroﬁlament, light polypeptide 221916_at 1.30E-20 3.57E-17
SCGN Secretagogin, ef-hand calcium binding protein 205697_at 5.44E-20 1.31E-16
HOXA10 Homeobox a13 213150_at 1.15E-19 2.46E-16
LOXL4 Lysyl oxidase-like 4 227145_at 1.68E-18 3.23E-15
HOXA13 Homeobox a13 231786_at 2.39E-18 3.95E-15
HOXD10 Homeobox d10 229400_at 3.88E-18 5.74E-15
CYTL1 Cytokine-like 1 219837_s_at 7.15E-18 9.83E-15
MYH2 Myosin, heavy polypeptide 2 204631_at 3.76E-16 4.82E-13
HSPB3 Heat schock 27 kDa protein 3 206375_s_at 1.06E-15 1.27E-12
HOXA11 Homeobox a11 213823_at 1.12E-15 1.27E-12
CFC1 Criptic family 1 223753_s_at 4.58E-15 4.90E-12
Genes underexpressed in myxopapillary ependymoma
APBA2 Amyloid beta (a4) precursor protein-biding, family a, member 2 209871_s_at 6.34E-12 4.36E-09
GPM6A Glycoprotein m6a 209470_s_at 6.34E-11 3.49E-08
MLC1 Megalencephalic leukoencephalopathy with subcortical cysts 1 213395_at 3.29E-10 1.29E-07
ABTB2 Ankyrin repeat and btb (poz) domain containing 2 213497_at 1.13E-09 3.95E-07
RNF43 Ring ﬁnger protein 43 218704_at 1.16E-09 3.99E-07
NCAN Chondroitin sulfate proteoglycan 3 205143_at 6.37E-09 1.80E-06
KIAA0644 Kiaa0644 gene product 205150_s_at 6.66E-09 1.86E-06
SLC35F1 Solute carrier family 35, member f1 228060_at 1.50E-08 3.96E-06
PKIA Protein kinase inhibitor alpha 204612_at 1.60E-08 4.11E-06
HNT Neurotrimin 227566_at 1.99E-08 4.91E-06
CDH4 Cadherin 4 206866_at 2.81E-08 6.68E-06
BIVM Basic immunoglobulin-like variable motif 222761_at 3.64E-08 8.15E-06
DBI Diazepam binding inhibitor 202428_x_at 4.86E-08 1.08E-05
GRAMD1B Gram domain containing 1b 218834_s_at 2.02E-07 3.77E-05
DDR2 Discoidin domain receptor family, member 2 205320_at 2.10E-07 3.89E-05
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small nuclear protein (PRAC); HOXB13; adp-ribosylation factor-
like 15 (ARL15); homeobox C10 (HOXC10); and neuroﬁlament
light polypeptide 68 kDa (NEFL). Downregulated genes included
amyloid beta precursor protein-binding, family a member 2
(APBA2); glycoprotein m6a (GPM6A); megalencephalic leukoen-
cephalopathy with subcortical cysts 1 (MLC1); ankyrin repeat and
btb domain containing 2 (ABTB2); and ring ﬁnger protein 43
(RNF43).
Three genes of interest were selected for further study. HOXB13
and NEFL were selected because they were among the ﬁve most
highly expressed genes. PDGFRa was selected due to its potential
therapeutic implication. HOXB13 is one of 20 HOX family genes
signiﬁcantly upregulated in MEPN compared to intracranial EPN
(891-fold higher, P = 7.8E-33). Figure 2 displays homeobox
family gene expression in pediatric MEPN compared to pediatric
intracranial EPN. Homeobox family genes were chosen for further
study due to the large number of highly expressed genes, their
well-deﬁned role in embryonic development and emerging litera-
ture that they may be involved in oncogenesis. Although multiple
HOX family genes were overexpressed, HOXB13 was further
examined because it had the highest mRNA expression in MEPN.
NEFLwastheﬁfthmosthighlyexpressedgeneinMEPN(1098-
fold higher, P = 1.3E-20). Overexpression of NEFL in MEPN is an
unexpected ﬁnding, as NEFL is an intermediate ﬁlament expressed
in neurons. Additional study was conducted to verify and deﬁne
NEFL protein expression in MEPN. PDGFRa was signiﬁcantly
overexpressed in MEPN (137-fold higher, P = 3.8E-5, q = 2.1E-3).
Although PDGFRa was not among the most highly expressed
genes, it was selected and studied due to its potential role as a
therapeutic target. PDGFRa is a receptor tyrosine kinase involved
intumorangiogenesisandmaintenanceofthetumormicroenviron-
ment (26). Several PDGFRa inhibitors are U.S. Food and Drug
Administration (FDA)-approved.
In addition to MEPN and intracranial EPN, comparative gene
expression analysis of HOXB13, NEFL and PDGFRa was
expanded to include a variety of pediatric CNS tumors. Of the
three genes examined, overexpression of HOXB13 was unique
to MEPN, while overexpression of NEFL and PDGFRa was
observed in other pediatric CNS tumors. Consistently low
Figure 2. Homeobox family gene expression
in pediatric myxopapillary ependymoma
compared to pediatric intracranial
ependymoma. Data are organized in a heat
map format where each row represents a
single gene and each column represents an
ependymoma sample. Genes are ranked
according to difference in expression between
MEPN and intracranial EPN. Normalized
z-scores correlating to the abundance of
mRNA relative to a common reference are
represented by a color scale where red
indicates high gene expression and green
indicates low gene expression. Abbreviations:
MEPN = myxopapillary ependymoma;
EPN = ependymoma; HOX = homeobox.
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CNStumorsincludingGBM,LCM,MEDandPA.ATRTdisplayed
moderate HOXB13 expression; however, expression in ATRT was
315-fold lower than MEPN. NEFL expression varied across differ-
ent tumor types. Lowest NEFL gene expression was found in
intracranial EPN followed by PA and MED. NEFL was moderately
expressed in ATRT and GBM and highly expressed in LCM. In
additiontoMEPN,PDGFRawashighlyexpressedinPAwithlittle
variation. Expression of PDGFRa greatly varied across individual
specimens inATRT, LCM, and MED.
Immunohistochemical Analysis of HOXB13,
NEFL, and PDGFRa Protein in MEPN Compared
to Intracranial EPN, SEPN, Spinal EPN, and
Adult and Fetal Ependyma
Immunohistochemical staining was performed on 13 MEPN, 13
intracranial EPN, 8 spinal EPN and 5 SEPN. The study numbers
were expanded by utilizing adult EPN types as described in the
methods.The rarity of SEPN and spinal EPN in the pediatric popu-
lation also necessitated including adult patients with these types of
EPNintheIHCportionofthestudy.ResultsoftheIHCstainingare
summarizedinTable 2.ImmunostainingofHOXB13wasconﬁned
to the nucleus. NEFL and PDGFRa staining was cytoplasmic. All
three antibodies demonstrated higher protein expression in MEPN
than intracranial EPN. No signiﬁcant differences were detected
between adult and pediatric protein expression levels of HOXB13,
NEFL, or PDGFRa in MEPN or intracranial EPN. Overall, the
upregulation of HOXB13, NEFL, and PDGFRa in MEPN identi-
ﬁed by gene expression microarray was recapitulated at the protein
level as measured by IHC.
Nineof13MEPNwerepositiveforHOXB13,includingasingle
case of incidental adult MEPN found in a ﬁlum terminale resected
for tethered cord syndrome. All SEPN and infratentorial EPN
specimens were negative for HOXB13. Two of six supratentorial
EPN were positive for HOXB13 with focal staining of individual
cells (+). One of eight spinal EPNs displayed strong staining for
HOXB13 (++), while seven of the eight spinal EPN were negative.
No staining was identiﬁed in the adult spinal cord sections, includ-
ing the ependyma of the sacral cord, ﬁlum terminale or the paren-
chyma of either of these two sites. The fetal ependyma specimens
of 18, 23 and 35 weeks’ gestation were negative for HOXB13.
Overall, HOXB13 had high sensitivity and speciﬁcity for MEPN,
especially for cases with the strongest (++) level of staining.
Figure 3 displays examples of HOXB13 IHC staining patterns,
as detailed in Table 2. Strong and diffuse nuclear staining of
HOXB13, scored as ++, in a pediatric MEPN is shown in
Figure 3A. In areas with perivascular pseudorosette formation, the
ependymoma cytoplasm clearly showed negative immunoreactiv-
ity, as did the endothelial cell nuclei of the blood vessel in the
center of the pseudorosette (Figure 3B). Strong HOXB13 nuclear
immunoreactivity was also found in adult MEPNs, as illustrated by
the example with strong and diffuse nuclear staining, scored as ++,
illustrated in Figure 3C and D. Spinal EPNs were generally nega-
tive for HOXB13, but a single strong (++) case is illustrated in
Figure 3E. All negatively stained cases demonstrated crisp and
contrasting “positive versus negative” qualities for the commercial
HOXB13 antibody used in this study.
Eight of 13 MEPN were positive for NEFL. Absence of NEFL
staining was observed in all SEPN and all supratentorial EPN.Two
cases of spinal EPN (2/8) and one case of infratentorial EPN (1/5)
werescoredasstrong(++)forNEFL.NEFLwasseenonlyinaxons
of the spinal cord and ﬁlum terminale and not in the ependymal
lining of the normal adult specimens. The fetal ependymal lining
specimens of 18, 23 and 35 weeks’ gestation were also negative for
NEFL.Ingeneral,IHCforNEFLatthestrong(++)levelhadahigh
sensitivityforMEPN,with8/13casespositiveforNEFLcompared
to 9/13 positive for HOXB13.There was somewhat lower speciﬁc-
ity for MEPN with NEFL than with HOXB13, since three non-
MEPN EPN variants also showed (++) staining.
Figure 4 presents examples of NEFL immunostaining patterns.
A pediatric and adult MEPN with strong and diffuse cytoplasmic,
ﬁbrillary staining are shown in Figure 4A and B, respectively. The
pediatric MEPN in Figure 4C shows cytoplasmic staining in areas
of the tumor with ependymal epithelial-like features and a
non-ﬁbrillary appearance. Figure 4D is an example of an adult
MEPN that stained with slightly less intensity, albeit still in a
sufﬁciently diffuse pattern to achieve a score of ++. Figure 4E
shows an adult MEPN with focal NEFL staining, yielding a score
of+.AllSEPNwerenegativeforNEFL,asillustratedbyFigure 4F.
Allbut2ofthe13MEPNspecimenswerepositiveforPDGFRa.
The negative MEPN specimens gave the impression of ﬁxation
issues, with extremely weak and edge-related staining that was
indeterminate. Four out of the ﬁve SEPN were negative for
PDGFRa. The ependyma of the ﬁlum terminale (specimens taken
from ﬁve adults without neurological disorders) showed moderate
or focal (+) immunoreactivity in 4/5 cases and strong (++) immu-
noreactivity in the remaining case. Immunostaining was conﬁned
to cells in the parenchyma of the adult spinal cord; these cells had a
satellite appearance, possibly suggestive of astrocytic cells. No
ependymalimmunostainingwasseeneitherinadultterminalsacral
cordorﬁlumterminale.Thefetalependymasectionswerenegative
for PDGFRa. IHC for PDGFRa demonstrated high sensitivity
but poor speciﬁcity for MEPN since most infratentorial and
supratentorial EPN were positive. Of all the EPN types, the least
overlap for PDGFRa was seen with the SEPN group.
Table 2. Summary of immunohistochemical staining of HOXB13, NEFL
and PDGFRa. Immunostaining was scored from - to ++ on a subjec-
tive scale. Twenty-ﬁve percent to 100% of cells staining yielded a
score of ++. Very focal staining in individual cells yielded a score of +.
Absence of staining was given a - designation. Abbreviations: MEPN =
myxopapillary ependymoma; spinal EPN = spinal ependymoma;
SEPN = subependymoma; EPN ST = supratentorial ependymoma; EPN
IF = infratentorial ependymoma; HOXB13 = homeobox B13; NEFL =
neuroﬁlament light; PDGFRa=platelet-derived growth factor receptor
alpha.
Diagnosis HOXB13 NEFL PDGFRa
-++ +-++ +-++ +
MEPN 4 1 8 5 1 7 2 0 11
Spinal EPN 7 0 1 6 0 2 2 1 4
SEPN 5 0 0 5 0 0 4 1 0
EPN ST 4 2 0 7 0 0 1 1 5
EPN IF 3 0 0 4 0 1 1 1 4
Adult ependyma 5 0 0 5 0 0 0 4 1
Fetal ependyma 3 0 0 3 0 0 3 0 0
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Figure 5. Figure 5A and B display a pediatric MEPN with diffuse
immunoreactivity, scored as ++. A second pediatric MEPN case
with strong, diffuse staining of PDGFRa is shown in Figure 5C
and D. Again, immunoreactivity appeared to occur regardless of
an ependymal epithelial-like versus ﬁbrillary phenotype, as illus-
trated in Figure 5C and D. Blood vessel walls and endothelial
cells were negative (Figure 5C). The adult spinal EPN in
Figure 5E shows diffuse, albeit less intense immunoreactivity,
scored as ++. Another case of adult spinal EPN is illustrated
in Figure 5F and shows strong intensity, but a lower staining
pattern.
Figure 3. Representative immunohistochemical staining of homeobox
B13 (HOXB13). Immunostaining was scored from - to ++ on a subjective
scale. Twenty-ﬁve percent to 100% of cells staining yielded a score of
++. Very focal staining in individual cells yielded a score of +. Absence of
staining was given a - designation. A. Strong and diffuse nuclear staining
of HOXB13, scored as ++, is illustrated in a pediatric myxopapillary
ependymoma (MEPN). Immunohistochemistry for HOXB13 with light
hematoxylin counterstain, original magniﬁcation 400¥. B. Higher power
magniﬁcation of the same pediatric MEPN depicted in A demonstrates a
perivascular pseudorosette with absence of HOXB13 staining in endot-
helial cell nuclei, original magniﬁcation 600¥. C. Photomicrograph of an
adult MEPN with diffuse expression, scored as ++, albeit with slightly
less intensity is shown. Immunohistochemistry for HOXB13 with light
hematoxylin counterstain, original magniﬁcation 200¥. D. The same
adult MEPN as shown in C is depicted at a higher magniﬁcation, original
magniﬁcation 400¥. E. Positive HOXB13 immunostaining reaching a
score of ++ was identiﬁed only in a single adult spinal ependymoma, as
illustrated in this photomicrograph. Immunohistochemistry for HOXB13
with light hematoxylin counterstain, original magniﬁcation 400¥. F.
Photomicrograph of an adult MEPN with negative HOXB13 staining for
direct comparison with A–E. Immunohistochemistry for HOXB13 with
light hematoxylin counterstain, original magniﬁcation 400¥.
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Little is known about the biology of MEPN. Clinical trial design
requires a better understanding of tumor biology. This is particu-
larly relevant to pediatric MEPN, which have a higher recurrence
rate than adult MEPN.The present study uses microarray technol-
ogytoidentifyaberrantlyexpressedgenesinpediatricMEPNcom-
pared to pediatric intracranial EPN. The overexpression of three
Figure 4. Representative immunohistochemical staining of neuroﬁla-
ment light polypeptide (NEFL). Immunostaining was scored from - to ++
on a subjective scale. Twenty-ﬁve percent to 100% of cells staining
yielded a score of ++. Very focal staining in individual cells yielded a score
of +. Absence of staining was given a - designation. A. Photomicrograph
of a pediatric myxopapillary ependymoma (MEPN) with strong and
diffuse cytoplasmic staining in ﬁbrillary areas of tumor, scored as ++.
Immunohistochemistry for NEFL with light hematoxylin counterstain,
original magniﬁcation 200¥. B. Photomicrograph at higher power shows
the perivascular, perpendicularly oriented cell processes surrounding
hyalinized blood vessels strongly immunoreactive for NEFL; this adult
MEPN achieved a ++ score. Immunohistochemistry for NEFL with light
hematoxylin counterstain, original magniﬁcation 400¥. C. Photomicro-
graph of a pediatric MEPN showing strong, diffuse cytoplasmic staining
in areas of the tumor with ependymal, epithelial, non-ﬁbrillary morpho-
logical features; this case scored as ++. Immunohistochemistry for NEFL
with light hematoxylin counterstain, original magniﬁcation 400¥. D. Pho-
tomicrograph of an adult MEPN with ++ diffuse immunoreactivity and
slightly less intensity. Immunohistochemistry for NEFL with light hema-
toxylin counterstain, original magniﬁcation 400¥. E. Focal immunostain-
ing for NEFL in an adult MEPN, yielding a + score. Immunohistochemis-
try for NEFL with light hematoxylin counterstain, original magniﬁcation
400¥. F. All subependymomas manifested absence of NEFL staining, as
illustrated in this adult example. Immunohistochemistry for NEFL with
light hematoxylin counterstain, original magniﬁcation 200¥.
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lated by IHC.
Numerous HOX family genes were found to be overexpressed in
MEPN compared to intracranial EPN. This ﬁnding was veriﬁed in
part by immunohistochemical staining of HOXB13. As predicted
by the microarray data, HOXB13 protein was more highly
expressed in MEPN than intracranial EPN. Overexpression of
homeobox genes by microarray analysis of mRNA has been previ-
ouslyreportedinspinalEPNbutnotMEPN.AstudybyTayloret al
reported HOX family genes to be overexpressed in spinal EPN
Figure 5. Representative immunohistochemical staining of platelet-
derived growth factor receptor alpha (PDGFRa). Immunostaining was
scored from - to ++ on a subjective scale. Twenty-ﬁve percent to 100%
of cells staining yielded a score of ++. Very focal staining in individual
cells yielded a score of +. Absence of staining was given a - designation.
A. Low power photomicrograph of a pediatric myxopapillary ependy-
moma (MEPN) with diffuse immunoreactivity for PDGFRa, scored as ++.
Immunohistochemistry for PDGFRa with light hematoxylin counter-
stain, original magniﬁcation 200¥. B. Photomicrograph at higher power
of the same tumor shown in A demonstrates the diffuse cytoplasmic
staining throughout all tumor cells of this perivascular pseudorosette.
Immunohistochemistry for PDGFRa with light hematoxylin counter-
stain, original magniﬁcation 400¥. C. Photomicrograph of a different
pediatric MEPN also manifests diffuse immunoreactivity, with diffuse
staining scored as ++. Immunohistochemistry for PDGFRa with light
hematoxylin counterstain, original magniﬁcation 200¥. D. Photomicro-
graph from a different area of the same case as illustrated in C demon-
strates that epithelial-like areas of the MEPN show strong immunoreac-
tivity. Original magniﬁcation 200¥. E. Photomicrograph of an adult spinal
ependymoma (EPN) with diffuse, albeit less intense immunoreactivity,
scored as ++. Immunohistochemistry for PDGFRa with light hematoxy-
lin counterstain, original magniﬁcation 200¥. F. Photomicrograph of a
different example of adult spinal EPN shows strong intensity but a lower
staining pattern (++, 400¥).
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(39). Palm et al also reported signiﬁcant overexpression of HOX
family genes in 14 spinal EPN and two EPN from the ﬁlum termi-
nale (27). The authors did not stipulate whether their ﬁlum termi-
nale examples had MEPN morphology.Although the present study
did not include spinal EPN in the microarray analysis, HOXB13
protein expression was not observed in 7 of the 8 spinal EPN.This
discrepancy may be due to differences in experimental approach,
i.e. protein expression by IHC versus gene expression by mRNA
microarray analysis.
The HOX family of genes speciﬁes the patterning of body seg-
ments along the anterior–posterior axis by encoding homeodomain
transcription factors essential for embryonic development (4, 20).
HOX groups 10–13 are associated with the lumbar/sacral region
where MEPN arise (43). Accordingly, the four most upregulated
HOX genes in MEPN were HOXB13, HOXC10, HOXA13 and
HOXD10. Thus, overexpression of HOX groups 10–13 in MEPN
may potentially be a function of location. However, normal adult
and fetal spinal ependyma and ﬁlum terminale were negative for
HOXB13 by IHC. Relatively late gestational time periods were
available for study (i.e. three fetuses of 18, 23 and 35 weeks’
gestation) and HOXB13 might well have been present at earlier
gestational time periods. It is probable that HOX groups 10–13 are
expressed in lumbar ependyma early in fetal development and then
switchedofffollowingsegmentation.ThatHOXB13wasnotfound
in normal fetal and adult ependyma suggests that HOX genes are
aberrantly expressed in MEPN.
Growing evidence indicates that abnormal HOX gene expres-
sion may be involved in oncogenesis. Aberrant HOX gene expres-
sion has been noted in acute myeloid and mixed lineage leukemia
(9, 13, 18), breast (29), cervical (34), non-small cell lung (28),
ovarian (6), prostate (42), skin (24) and thyroid cancers (38). The
overexpression of HOX genes in MEPN combined with their
potential oncogenic function suggests that the HOX family should
be evaluated as a potential therapeutic target. The design of HOX
family inhibitors is currently being studied, but is hindered by
the functional redundancy of HOX transcription factors and the
common co-expression of multiple HOX genes (28).
NEFL was highly overexpressed in MEPN. Neuroﬁlament light
polypeptide (68 kDa) is a Class IV intermediate ﬁlament expressed
in neurons (44).Two homeobox genes that are signiﬁcantly overex-
pressed in MEPN compared to intracranial EPN, HOXA3 and
HOXA9, have transcription-factor binding sites near the NEFL
gene(40).Furtherresearchisneededtodetermineiftheconcurrent
expression of these genes is related. Although the high expression
of NEFL is signiﬁcant to the molecular biology of MEPN, it is a
poor therapeutic target due to its ubiquitous expression in axonal
processes.
Upregulation of PDGFRa in MEPN suggests that therapeutic
targeting of this receptor tyrosine kinase may be an appropriate
candidate for future clinical trials. Several PDGFRa inhibitors are
FDA-approved, including imatinib mesylate, sorafenib and suni-
tinib (1–3). Although MEPN response to PDGFRa inhibitors is
currently unknown, Fakhrai et al reported a case study in which a
recurrent spinal ependymoma with positive PDGFRa IHC demon-
strated partial remission during treatment with imatinib mesylate
(15).
An acknowledged limitation of this study is the relatively small
number of pediatric MEPN available for gene expression proﬁling
(n = 5). It should be noted, however, that rapidly frozen surgical
specimens are required for this gene expression microarray tech-
nique and MEPN are not common in the pediatric age group.
Indeed, at the busy tertiary care pediatric hospital where the speci-
mens were obtained, the ﬁve MEPN represent virtually every
MEPN seen at the institution and accrued over the past 10 years.
Thus, it is not surprising that the current study presents the largest
cohort to date in the literature that examined pediatric MEPN.The
number and diversity of EPN types was increased by including
adult patients for the IHC portion of this study, as compared to the
gene expression microarray portion of the study which was con-
ﬁned to pediatric MEPN and pediatric EPN. This allowed us to
include two adult EPN types that are seldom found in pediatric
patients, i.e. SEPN and spinal EPN.
Literature on the molecular biology of MEPN is scarce and
impedes progress in the treatment of recurrent tumors. The
present study sought to address a speciﬁc clinical problem in a
grade of tumor that has received relatively little attention despite
its ability to recur and disseminate.The study reports the top over-
and underexpressed genes in pediatric MEPN that distinguish
them from intracranial EPN and identiﬁes at least one potential
therapeutic target for recurrent MEPN. Future studies with larger
cohorts are needed to conﬁrm our microarray and protein expres-
sion ﬁndings.
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SUPPORTING INFORMATION
Additional Supporting Information may be found in the online
version of this article:
Table S1. Cohort demographics including patient diagnosis, age at
diagnosis, gender and tumor grade. Grade denotes the histological
grade as deﬁned by the World Health Organization classiﬁcation
of tumors of the central nervous system. The table indicates if
specimens were included in the gene expression microarray or
immunohistochemistry cohorts (Microarray or IHC, respectively).
Abbreviations: dx = diagnosis; MEPN = myxopapillary ependy-
moma; ST EPN = supratentorial ependymoma; IF EPN =
infratentorial ependymoma; SP EPN = spinal ependymoma;
SEPN = subependymoma; NE = normal ependyma (spinal cord
sections); M = male; F = female;Y = yes; N = no.
Please note:Wiley-Blackwell are not responsible for the content or
functionality of any supporting materials supplied by the authors.
Any queries (other than missing material) should be directed to the
corresponding author for the article.
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